Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy.

Détails

ID Serval
serval:BIB_3B2EF85641A5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy.
Périodique
International journal of cardiology
Auteur(s)
Vergaro G., Del Franco A., Giannoni A., Prontera C., Ripoli A., Barison A., Masci P.G., Aquaro G.D., Cohen Solal A., Padeletti L., Passino C., Emdin M.
ISSN
1874-1754 (Electronic)
ISSN-L
0167-5273
Statut éditorial
Publié
Date de publication
01/04/2015
Peer-reviewed
Oui
Volume
184
Pages
96-100
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Left ventricular (LV) fibrosis, assessed by late gadolinium enhancement (LGE) at cardiac magnetic resonance imaging (MRI), is a marker of LV remodeling, and holds prognostic value in nonischemic dilated cardiomyopathy (NICM). Galectin-3 has been shown to participate in tissue fibrogenesis and to be a prognosticator in heart failure. Our aim was to investigate the relationships between galectin-3 circulating level and myocardial fibrosis at MRI in patients with NICM.
One-hundred-fifty patients were enrolled (males 73%; age 58, SD 14 years), with a NICM diagnosis according to the World Health Organization criteria. All patients underwent a comprehensive clinical assessment and biohumoral characterization, including galectin-3 assay, and cardiac MRI, with LGE assessment of fibrosis. Median galectin-3 value was 14.4 ng/mL (IQR 11.7-19.0 ng/mL), and LGE was detected in 106 (71%) patients. Patients with LGE had higher galectin-3 than those without (15.4, 11.8-21.0, vs 13.1, 11.7-16.4 ng/mL, p=0.006). Among univariate predictors of LGE presence (galectin-3, male sex, disease duration, arterial hypertension, left and right ventricular ejection fraction, left ventricular stroke volume), galectin-3 maintained its predictive value at multivariate analysis, together with sex, hypertension, disease duration and right ventricular ejection fraction. At receiver operating characteristic analysis the optimal galectin-3 cut-off for LGE prediction was 14.6 ng/mL (AUC 0.651, sensitivity 57%, specificity 73%).
Galectin-3 is associated with LGE-assessed myocardial replacement fibrosis in patients with NICM. These results support the hypothesis that galectin-3 is involved in cardiac fibrosis and remodeling in NICM, and that its assay may help to select subgroups at higher risk.

Mots-clé
Adult, Aged, Biomarkers/blood, Cardiomyopathy, Dilated/blood, Cardiomyopathy, Dilated/diagnosis, Cohort Studies, Female, Fibrosis/blood, Fibrosis/diagnosis, Galectin 3/blood, Humans, Male, Middle Aged, Myocardium/metabolism, Myocardium/pathology, Prospective Studies, Biomarkers, Cardiomyopathy, dilated, Late gadolinium enhancement, Magnetic resonance imaging, Myocardial fibrosis
Pubmed
Web of science
Création de la notice
25/08/2017 21:23
Dernière modification de la notice
20/08/2019 14:31
Données d'usage